Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
-Phase 1a trial demonstrated acceptable safety and tolerability with no reported serious adverse events-Phase 1a data demonstrated target engagement, a...
Month: April 2024
Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules
- $17.5 million upfront proceeds with up to an additional $175 million of proceeds upon the exercise of warrants- Initial capital funds...
Amphastar Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / April 1, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO,...